DENVER — Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients
with epidermal growth factor receptor (EGFR) mutations.
Patients
with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.
Not exact matches
High total and saturated fat intake were associated
with greater risk of estrogen
receptor - and progesterone
receptor - positive (ER+PR +) breast cancer (BC), and human
epidermal growth factor 2
receptor - negative (HER2 --RRB- disease, according to a new study published April 9 in the Journal of the National Cancer Institute.
Clinically important findings suggest that targeting the
epidermal growth factor receptor (EGFR) and the fibroblast
growth factor receptor (FGFR) cellular pathways may benefit thousands of patients
with this disease, according to the study published today in the journal PLOS Genetics.
That protein, CRKII, interacts
with another protein called an
epidermal growth factor receptor.
Multiplexed genetic screening for
epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared
with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.
The study, called the PALOMA - 3, enrolled 521 pre - / peri - and postmenopausal patients
with hormone
receptor positive and human
epidermal growth factor receptor - negative (HR + / HER2 --RRB- advanced disease.
Among patients
with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared
with treatment using
epidermal growth factor receptor tyrosine kinase inhibitors, was associated
with improvement in survival without progression of the cancer, but not
with overall survival, according to a study in the April 9 issue of JAMA.
Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well
with the EGFR mutations from patient - matched tumor tissue DNA.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients
with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene.
The analysis also found that Asian / Pacific Islander women were more likely to be diagnosed
with another subtype of breast cancer: so - called human
epidermal growth factor receptor 2 (HER2)- overexpressing breast cancer.
The advent of therapies directed at tumors
with mutations in
epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and B - Raf proto - oncogene (BRAF) genes over the past decade have dramatically changed outcomes, he says.
Triple - negative cancers are so called because they do not express
receptors for the hormones estrogen and progesterone, nor for HER2 (human
epidermal growth factor 2), and hence patients
with these cancers are not candidates for treatment
with modern hormonal therapies or the highly effective HER2 - targeted drug Herceptin (trastuzumab).
Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients
with NSCLC have a mutation in the
epidermal growth factor receptor (EGFR), which can be successfully targeted
with EGFR inhibitors called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib.
He examines several well - studied
receptors — the bacterial aspartate
receptor (Tar), human
epidermal growth factor receptor (EGFR), and human brain - derived neurotrophin
receptor (BDNFR)-- and comes to a conclusion that they all have similar chemical structures
with or without their corresponding ligands.
Josef Singer and Judith Fazekas, both lead authors of the study, discovered that a
receptor frequently found on human tumor cells (
epidermal growth factor receptor or EGFR) is nearly 100 percent identical
with the EGF
receptor in dogs.
PALLAS: Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib
with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone
Receptor Positive (HR +) / Human
Epidermal Growth Factor Receptor 2 (HER2)- Negative Early Breast Cancer
An Open Label, Phase II Study of Neratinib in Patients
with Solid Tumors
with Somatic Human
Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification
With this technology, they could watch for responses as cancer cells responded to signals from EGFR (
epidermal growth factor receptor).
GEP testing is recommended for patients
with early - stage, node - negative, estrogen
receptor (ER)-- positive, human
epidermal growth factor 2 (HER2)-- negative cancers.
Mucosal melanomas
with mutations in CDK4 may respond to palbociclib or ribociclib, which have demonstrated activity in advanced hormone
receptor — positive, human
epidermal growth factor receptor 2 — negative breast cancer.
Along the same lines, in non-small cell lung cancer (NSCLC), acquired resistance to Gefitinib / Erlotinib kinase inhibitors has also been associated
with a secondary mutation of the gatekeeper Thr790 residue of the
epidermal growth factor receptor (EGFR).
Epidermal growth factor receptor, also called EGFR, is a biomarker found in certain patients
with lung cancer.
In addition to RIPK2 binding as part of this computer - based (initial) screening, we selected compounds that inhibited
epidermal growth factor receptor (IC50 values > 1000 nM; weak inhibitory activity) along
with weak binding interactions in the EGFR and c - ABL binding sites, two common off - targets for previously identified RIPK2 inhibitors.
The discovery of how the
epidermal growth factor receptor (EGFR) is activated offers insight into how current EGFR - blocking drugs interact
with the
receptor and an important avenue for the...
These results, also presented at the 2015 European Cancer Congress (ECC2015, abstract # 5BA) today, which involve the group of 1,626 patients
with a Recurrence Score between 0 and 10, demonstrated that 99.3 percent of node - negative, estrogen
receptor (ER)- positive, human
epidermal growth factor receptor 2 (HER2)- negative patients who met accepted guidelines for recommending chemotherapy in addition to hormonal therapy, had no distant recurrence at five years after treatment
with hormonal therapy alone.
In highly proliferative lesions
with increased Ki67, estrogen
receptor was negative, but human
epidermal growth factor receptor 2 was usually positive
with a distribution that was similar to that reported for human intraepithelial lesions (7).